Introduction
and EGF receptor seems to be indirect (14, 15) . Thus, activation mechanism under physiological conditions of the normal SFKs is not well understood.
The adaptor protein Shc is another proto-oncogene product that has no intrinsic catalytic activity (16) . The molecular mechanism by which Shc causes malignant cell transformation is not known. However, Shc possesses at least three tyrosine phosphorylation sites in its central collagen-homology domain and two phosphotyrosine-binding domains, one SH2 domain in the carboxy-terminus and another phosphotyrosine-binding (PTB) domain in the amino-terminus (17) . So, it has been assumed that Shc will work as an adaptor molecule to mediate phosphotyrosinedependent signaling events near the cell surface receptors. In fact, many studies demonstrated that several receptor PTKs have tyrosine autophosphorylation sites which bind to Shc, and that the receptor-bound Shc becomes tyrosine-phosphorylated by the receptor and recruits another SH2-containing adaptor protein, Grb2, to the phosphotyrosine residues. The activated receptor-Shc-Grb2 complex then triggers the Ras-mediated MAP kinase cascade through a Ras-activating molecule, Sos (18) . It is also observed that Shc plays a role in the downstream signaling of non-kinase receptors, such as T-cell receptor, integrins, and G protein-coupled receptors (17) . In this case, cytoplasmic PTKs seem to be responsible for the Shc phosphorylation. However, it is not clear how cytoplasmic PTKs are activated and interact with Shc. Another important issue is that Shc is usually expressed as three isoforms, P46, P52 and P66, in many types of cells. These isoforms are produced from one gene by alternative splicing and alternative translation (19) . When the production of P66 isoform was specifically blocked in P66-knockout mice, the mice showed prolonged viability under the oxidative stress (20) . So, there might be isoform-specific functions for Shc proteins. Until now, however, the functional difference between the P46 and P52 isoforms has not been demonstrated.
Recently, we have found that overexpression of P52 and P66 Shc isoforms, but not P46 isoform, induce c-Src activation in A431 human epidermoid carcinoma cells (14) . This finding prompted us to examine a direct interaction between Shc and c-Src molecules and the effect of the interaction on c-Src activity in vitro and in vivo. We show here that Shc-mediated c-Src activation is resulted from a direct and site-specific interaction of Shc isoforms, namely P66 and P52 but not P46. The activation of c-Src is not accompanied by the dephosphorylation of the carboxy-terminal phosphotyrosine residue that has been believed to be important for the up-regulation of c-Src. It is also demonstrated that the Shc-mediated activation of c-Src is enhanced by the EGF signaling and leads to tyrosine-phosphorylation of Stat transcription factors and activation of p21/WAF1/Cip1 pathway that has been implicated in cell cycle arrest and subsequent apoptosis of the A431 cells (21) (22) (23) (24) .
Experimental Procedures
Cells-A431 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Subconfluent cells were transfected for 24 hours with plasmid DNAs encoding GFP-fusion Shc isoforms (see below) by using Effectene reagent (Qiagen, Germany), serum-starved for 18 hours, and stimulated with or without 10 nM EGF (Upstate Biotechnology, NY, USA) as described previously (14) .
Plasmids and recombinant proteins-Plasmids for bacterial or mammalian expression of GST-and GFP-fusion forms of mouse Shc were constructed as described (14) . DNAs encoding a series of fragment of mouse P52 Shc were generated by polymerase chain reaction (PCR) of mouse shc gene using the appropriate sets of sense and antisense primers and subcloned into pGEX-2T (Pharmacia) or pEGFP-C3 (Clonetech Laboratories) expression vector. A point-mutated version of the P52 Shc (M46P) was obtained by ligating two cDNAs encoding residues 1-49 and 46-469 of P52, in which the nucleic acid residues encoding methionine (ATG) at residue 46 have been substituted by those encoding proline (CTG). DNA encoding the activation segment of c-Src (residues 404-432) was generated by PCR amplification of the corresponding region using the chicken c-src gene, which was subcloned in p5H (25) , a gift from Dr. H. Hanafusa, as a template. The resulting DNA was purified and subcloned into pGEX-2T to be bacterially expressed as GST-fusion protein (GST-IDA). All GST-fusion proteins were purified by affinity column chromatography using glutathione Sepharose (Pharmacia).
Antibodies, purified enzymes, synthetic peptides, and other chemicals-AntiSrc (mAb327), anti-pY416, and anti-pY527 antibodies were obtained from Oncogene Research Products (MA, USA). Antibodies specific to the unphosphorylated Tyr-527 of c-Src (anti-Y527) or carboxyl-terminus of human EGF receptor (anti-EGF receptor) were prepared as described (15, 26) . Anti-Shc antibody was obtained from Upstate Biotechnology. Anti-pSTAT1 (phospho-Tyr-701), anti-pSTAT3 (phosphoTyr-705), and anti-pSTAT5b (phospho-Tyr-694) antibodies were obtained from Cell Signaling Technology (MA, USA).
Anti-phosphorylated p42/p44 MAP kinase antibody was obtained from BioLabs (MA, USA). Anti-p21/WAF1 antibody was obtained from Transduction Laboratories (KY, USA). c-Src, v-Src, and EGF receptor were prepared from bovine brain, Rous sarcoma virus-transformed mouse cells, and A431 cells, respectively, as described (15, 27) . Bovine heart type II PKA and cAMP were purchased from Sigma (MO, USA). Synthetic peptides (IDA peptides) that correspond to the activation segment of c-Src, MAP kinase, PKA, EGF receptor, or CDK1 and a tyrosine kinase substrate peptide (Cdc2 peptide: residues 7-26 of the fission yeast Cdc2) were prepared as described (14) . These antibodies and peptides were used at concentrations as specified in the text. The Src-specific inhibitor PP2 and its inactive analogue PP3 (28) were purchased from Calbiochem (USA).
Cell extraction, protein-tyrosine phosphorylation, enzyme assay, and molecular interaction-To analyze protein function in A431 cells, EGF-treated or untreated cells were extracted with buffer containing 1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 10 mM β-mercaptoethanol, 1 mM sodium orthovanadate, 10 µg/ml leupeptin, 20 µM (p-amidinophenyl)methanesulfonyl fluoride, and 20 mM Tris-HCl, pH 7.5. Protein concentration was determined by the dye-binding assay using a BioRad assay kit (Bio-Rad, CA, USA). Specified amounts of the extracted proteins (1 mg/ml protein) were subjected to examinations for tyrosine phosphorylation, coimmunoprecipitation, expression, subcellular localization, and enzyme activity of proteins by immunoprecipitation and/or immunoblotting as described (14) . For the analysis of nuclear localization of STAT3, nuclear fraction was prepared according to the described method (23) . Protein kinase activity was assessed by in vitro kinase assay in the presence of [γ-32 P]ATP (Moravek Biochemicals, CA, USA), a substrate peptide, and the specified amounts of effector molecules such as recombinant Shc proteins, synthetic IDA peptides, EGF, and cAMP. Kinase reaction was initiated by addition of [γ-32 P]ATP and allowed to proceed for 10 min at 30 o C. After terminating the reaction by boiling with SDS-containing buffer, phosphorylated peptide and protein were separated by SDS-PAGE and analyzed by BAS 2000 phosphoimage analyzer (Fujifilm, Tokyo, Japan).
Tyrosine phosphorylation state of c-Src was determined by immunoblotting with specific antibodies. Direct binding of recombinant Shc proteins to the activation segment of c-Src (GST-IDA, see above) was determined by surface plasmon resonance analysis using BIAcore 1000 (Pharmacia Biosensor AB, Sweden) according to the manufacturer's instructions. GST-IDA was immobilized onto a sensor tip that had been coated with carboxy-methylated dextran and activated with Nhydroxysuccinimide and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. Association of the Shc proteins with the immobilized GST-IDA was carried out in buffer supplied by the manufacturer at 25 o C for 600 seconds, and followed by wash treatment for 300 seconds. Dissociation constants between Shc and GST-IDA were calculated by employing software from BIA Evaluation (Pharmacia Biosensor AB). Affinity pull-down of cellular c-Src and Shc were carried out with recombinant Shc and GST-IDA, respectively. The reaction involved incubation of the specified amount of cell lysate with recombinant Shc and GST-IDA (1-5 µg protein) immobilized onto glutathione Sepharose beads at 30 o C for 30 min, and wash treatment of the beads with buffer containing 1% Triton X-100, 50 mM NaCl, 50 mM Tris-HCl, pH 7.5, to eliminate non-specific binding. Bound proteins in the washed beads were analyzed by SDS-PAGE, followed by immunoblotting and/or protein staining.
Results
Activation of c-Src by Shc overexpression leads to up-regulation of the Statp21/WAF1 pathway in A431 cells-We analyzed isoform-specific function of Shc in A431 cells that transiently express green fluorescent protein (GFP)-tagged Shc isoforms (Fig. 1A) . Since our previous studies have shown that EGF induces association of EGF receptor with c-Src and activation of c-Src (14, 15) we first confirmed the effect of Shc isoforms on the interaction between c-Src and EGF receptor. As shown in Fig. 1B , expression of GFP-Shc P52 or P66, but not P46, resulted in an augmentation of EGF-dependent association of c-Src with EGF receptor and caused an activation of c-Src in A431 cells. Both endogenous and GFP-tagged P52/P66 were co-immunoprecipitated with c-Src, but neither endogenous P46 nor GFP-P46 was associated with the c-Src-EGF receptor complex.
The result demonstrates that P52 and P66 but not P46 Shc can mediate up-regulation of both basal and EGF-stimulated activities of c-Src. We have also observed stimulation of the basal c-Src activity by overexpression of Shc P52/P66 in NIH3T3 cells (data not shown). Co-immunoprecipitation of Shc P52/P66 with c-Src suggests that the up-regulation of c-Src may involve a direct interaction of Shc molecules with c-Src.
To clarify the physiological consequence of this Shc isoform-specific c-Src activation, we have examined phosphorylation of Stat transcription factors and expression of p21/WAF1/Cip1, a cyclin-dependent kinase (CDK) inhibitor. It has been reported that EGF-induced tyrosine phosphorylation of Stat is dependent on c-Src activity in A431 cells (23) , and the phosphorylated Stat undergoes nuclear translocation and induces p21/WAF1/Cip1 expression (21) . As demonstrated in Fig. 1C , the EGFdependent Stat3 phosphorylation is sensitive to PP2, a Src-specific inhibitor, while phosphorylation of EGF receptor and EGF-dependent activation of p44/p42 MAP kinase are scarcely affected by the inhibitor.
Thus, the EGF-dependent Stat phosphorylation is a good indicator for EGF-dependent c-Src activation in this cell system. In Fig. 1D , we examined phosphorylation of Stat proteins in GFP-or GFPShc-expressing cells that had been pretreated with PP2 or PP3 (an inactive analogue of PP2) and incubated with or without EGF. We found phosphorylation of Stat1, Stat3, and Stat5b in all of the EGF-stimulated cells. Prominently, in the cells expressing GFP-Shc P52 or P66, Stat phosphorylation was observed even in the absence of EGF stimulation (lanes 9 and 13). Control cells expressing GFP alone or the cells expressing GFP-Shc P46 did not show such an EGF-independent activation of c-Src (lanes 1 and 5). Phosphorylation of Stat proteins was effectively inhibited by PP2. However, phosphorylation of Stat1 and Stat5b seemed to be less sensitive to PP2, when cells were stimulated with EGF. This result suggests that other PTKs, such as EGF receptor itself, may be partially involved in the phosphorylation of Stat1 and Stat5b. The phosphorylation of Stat3 was accompanied by its accumulation in the nucleus and well correlated with the expression of p21/WAF1/Cip1. Fig. 1D also shows phosphorylation state of c-Src that was monitored by immunoblotting with specific antibodies (lower panels). It is demonstrated that activation of c-Src by EGF stimulation or by the expression of GFP-P52/P66 involved the autophosphorylation of Tyr-416 in the activation segment of c-Src. Importantly, however, the activation of c-Src was not accompanied by dephosphorylation of the carboxy-terminal phosphotyrosine residue (pY527). The result implies that the EGFand Shc-dependent stimulation of c-Src activity is not resulted from an activation of phosphatase(s) that can dephosphorylate pY527.
In vitro activation of c-Src by Shc is Shc isoform-specific and independent of dephosphorylation of pY527-To examine whether Shc proteins can activate c-Src directly, we employed an in vitro reconstitution assay with purified proteins. We used down-regulated, i.e. enzymatically inactive but activatable, c-Src that was purified from bovine brain and glutathione S-transferase (GST)-tagged Shc isoforms expressed in E. coli. As shown in Fig. 2A , GST-P66 and P52, but not GST-P46 or GST alone, stimulated the activity of purified c-Src in a dose-dependent manner. This result strongly suggests that Shc isoform-specific c-Src activation is mediated by a direct interaction between c-Src and Shc molecules. As shown in Fig. 2B , the purified c-Src incubated with GST-P52 Shc underwent autophosphorylation at Tyr-416 under the in vitro assay conditions, but dephosphorylation of the carboxy-terminal pY527 was not observed (lanes 1 and 2). On the other hand, incubation of c-Src with alkaline phosphatase clearly reduced phosphorylation state of both sites (lane 3 and 4). These results indicate that the c-Src activation by Shc is not mediated by Shc-dependent stimulation of any phosphatase activity that may dephosphorylate pY527 and activate c-Src. It is also demonstrated in Fig. 2C , that the GST-P52-dependent kinase activation is specific to c-Src. The constitutively active v-Src, EGF receptor, and cAMP-dependent protein kinase were not stimulated by GFP-P52. The result eliminates the possibility that GST-P52 is a non-specific activator of protein kinases, for instance, an inhibitor of ATPase that may contaminate the in vitro assay system.
The activation segment of c-Src is responsible for the interaction with ShcWe have previously found that synthetic peptides corresponding to the activation segment of c-Src, named IDA (Inter-DFG-APE) peptides, can affect the interaction between c-Src and Shc-EGF receptor complex (14) . So we examined the effect of IDA peptides on the Shc-dependent activation of c-Src. As shown in Fig. 2D , activation of c-Src by GST-Shc P52 was inhibited by the IDA-Src peptide in a dose dependent manner. Phosphorylation of Tyr-416 in the peptide did not affect this inhibitory action. IDA peptides corresponding to other protein kinases (cAMP-dependent protein kinase, MAP kinase, EGF receptor/kinase, and CDK1) had no inhibitory effect on the c-Src activation by Shc. These results suggest that the interaction between c-Src and Shc involves the activation segment of c-Src and is independent of tyrosine phosphorylation state of the segment. To confirm this, we prepared IDA-Src peptide fused with GST (GST-IDA) and tested whether it can pull-down Shc molecules from cell extract. Fig.  2E shows that GST-IDA but not GST can bind to the endogenous Shc P52 in this affinity pull-down assay. However, apparent binding of Shc P66 was not detected in this experiment. We think this is probably because P66 is less abundant than P52 in the extract (see the first lane). Although isoform-specificity of the interaction was not confirmed by this experiment, it is demonstrated that the unphosphorylated activation segment of c-Src can bind to Shc.
An amino-terminal short segment in P52 Shc is responsible for the interaction with and activation of c-Src-To confirm the isoform-specific direct binding of Shc to the activation segment of c-Src, we have employed surface plasmon resonance analysis in which GST-IDA surface was tested for the interaction with GST-Shc isoforms (Fig.  3A) . P52 and P66 isoforms fused to GST were found to interact with GST-IDA, whereas GST-P46 or GST alone did not exhibit significant binding. Neither GST-P52 nor GST-P66 interacted with GST surface (data not shown). The dissociation constants (K D ) for GST-P52 and GST-P66 were calculated to be 1.8 + 0.4 x 10 -8 M and 5.3 + 0.8 x 10 -8 M, respectively. The result clearly demonstrates that the binding of Shc to cSrc is direct and isoform-specific.
To identify the c-Src-interactive site(s) in Shc molecule, we have prepared a series of recombinant Shc fragments and used them in an affinity pull-down experiment (Fig.  3B) . We found that GST-P52 but not GST-P46 interacted with c-Src in the extract of A431 cells. A fragment of P52 Shc having residues 1-45 still showed a notable binding toward c-Src. However, fragments shorter than this lost the binding capacity. Deletion of amino-terminal residues up to 28 from P52 Shc did not abolish the binding capacity. Therefore, binding capacity of Shc was mapped between residues 29-45 of P52 Shc in this assay. As shown in Fig. 3C , the affinity pull-down of c-Src with GST-Shc P52 was inhibited by the IDA peptide derived from c-Src but not by those from other protein kinases, confirming that GST-Shc P52 is interacting with c-Src via the activation segment of c-Src.
We also examined c-Src-binding capacities of Shc fragments by surface plasmon resonance analysis. The results obtained are summarized in Fig. 4 , along with those obtained for c-Src activation assays with the same Shc fragments. In addition to the Shc fragment having residues 1-45 that was positive in the pull-down assay (Fig. 3B) , a fragment corresponds to residues 1-39 was newly found to be capable of c-Src binding in this analysis. To our surprise, however, when we performed activation assay with these Shc fragments, they did not show any stimulating effect on the c-Src kinase activity.
This result indicates that the c-Src-binding capacity of Shc can be discriminated from the c-Src-activation ability as depicted in Fig. 4B . In other words, c-Src-binding of Shc is not sufficient for c-Src-activation.
A point mutation in P52 Shc results in the loss of c-Src-activation without affecting the c-Src-binding capacity-From a structural analysis of the PTB domain of Shc (29) , it has been shown that there are three α-helices in the PTB domain. The first α-helix (α1) is present in the c-Src-activation region of P52 Shc (residues [40] [41] [42] [43] [44] [45] [46] [47] . This helix is not included in the phosphophotyrosine-binding pocket of PTB domain. So, we assumed that any helix-disrupting mutation in this α1-helix might specifically abolish the c-Src-activating property of Shc without affecting the PTB function, for instance, binding to the activated EGF receptor. Moreover, such a mutation would not affect the c-Src-binding capacity of Shc, because it still has the region responsible for the c-Srcbinding ( Fig. 4A and B) . To test this hypothesis, we have constructed a point mutant, named M46P Shc, in which the amino acid residue Met-46 of P52 Shc was replaced by Pro. This substitution would reduce the helical propensity of the α1-helix region dramatically, as predicted in a Chou-Fasman analysis shown in Fig. 5A . As expected, the M46P mutant showed a dose-dependent association with GST-IDA surface with a K D of 2.7 + 0.6 x 10 -8 M (Fig. 5B) , which was similar to that of wild type Shc P52. However, the mutant had no c-Src-stimulating ability in the purified assay system (Fig.  5C) . Immunoprecipitation (Fig. 5D ) and immunolocalization studies (not shown) demonstrated that association of M46P Shc with c-Src and EGF receptor in A431 cells was similar to that of wild type P52, but the stimulation of basal and EGF-dependent activities of c-Src was greatly diminished in M46P Shc-transfected cells.
Finally, we examined the effect of M46P mutation on the Shc-dependent Stat signaling; i.e. phosphorylation of Stat proteins and p21/WAF1/Cip1 expression (Fig.  5E ). It is evident that EGF-dependent association of Shc with the receptor and subsequent phosphorylation of Shc proteins that are mainly mediated by the activated EGF receptor was not affected in M46P Shc-transfected cells (upper panels), indicating that PTB function of the M46P mutant is not impaired. However, if the cells were not stimulated with EGF, the activation of c-Src, as judged by anti-pY416, phosphorylation of Stat proteins, and p21/WAF1/Cip1 expression were substantially reduced in the M46P Shc-transfected cells in comparison with the wild type Shctransfected cells (lower panels). From these data we concluded that the M46P mutation of Shc abolished its c-Src-activating ability, and hence, reduced Stat-mediated p21/WAF1/Cip1 expression.
Discussion

Identification of the adaptor protein Shc as a novel direct activator of c-Src-Shc was
first isolated by an SH2-based DNA screening and found as a proto-oncogene product that promotes malignant transformation of NIH3T3 fibroblasts (16) . Recent studies by the same group have shown that P66 Shc isoform has a distinct function from that of P52/46 in the EGF-dependent MAP kinase-Fos signaling and that P66-specific cellular function is linked to anti-oxidative stress responses of cells that result in prolonged life span of the P66-knockout mice (19, 20) . However, functional differences between P52 and P46 have not yet been demonstrated. Our present findings provide a novel function of Shc that involves isoform-specific and kinase-activating interaction with the tyrosine kinase c-Src, a representative proto-oncogene product of the Src family. The SFKs and Shc are evolutionary conserved among multicellular organisms, and Shc is also known to be a substrate of SFKs (30) (31) (32) . Therefore, the signaling cross-talk between these proto-oncogene products may play a fundamental role in cell function. As an example of downstream elements of the Shc-Src interaction, we have identified Stat-p21/WAF1/Cip1 pathway. Previous reports have shown that, in A431 cells, Stat-p21/WAF1/Cip1 pathway is engaged in EGFdependent cell cycle arrest that leads to apoptotic death of the cells (21-24). Our observations are in good accordance with the above scenario in this cell line, although further study will be needed to clarify the role played by the Src-dependent phosphorylation sites of Stat in the induction of p21/WAF1/Cip1. However, it still remains unclear as to how Shc overexpression induces malignant cell growth of NIH3T3 fibroblasts (16) . The fact that Shc P66/P52 can induce c-Src-dependent phosphorylation of Stat proteins may explain this issue. Since Stat signaling has been shown to be required for cell transformation of NIH3T3 cells by v-Src (33-35), constitutive activation of c-Src by Shc overexpression would cause phosphorylation of Stat proteins similar to that by v-Src. Thus, the Shc-Src interaction may play a pivotal role in regulating cell cycle progression and cell survival depending on the cell types and growth conditions. In accordance with this, it has been demonstrated that Shc is in complex with the integrin-dependent cell cycle machinery (36) . Interestingly, in this system, a member of the SFKs, Fyn, has been identified as a direct or indirect Shc binding partner (37) . It will be important to test whether Shc can be a universal regulator of SFKs in many other cell systems.
Molecular mechanism of c-Src activation by Shc-Since the discovery of the enzymes responsible for the phosphorylation and dephosphorylation of the negative regulatory tyrosine phosphorylation site (Tyr-527 for chicken c-Src), in the carboxytermini of SFKs (8, 38, 39) , it has been believed that the major regulation mechanism of SFKs relies on the reversible phosphorylation of this critical tyrosine residue catalyzed by these regulatory enzymes. However, later X-ray crystallographic studies on the down-regulated, i.e. enzymatically inactive by co-expression with Csk, c-Src and Hck have suggested that proteins that will interact with the non-catalytic domain of SFK could displace the inactive conformation of SFK to the active one (9, 10, 40) . Actually, several SH2 and/or SH3-binding proteins have been identified as direct activators of cSrc and other SFKs. For example, Alexandropoulos and Baltimore (41) demonstrated that Sin (Src-interacting or signal-integrating protein), a Cas-related adaptor protein, binds to both SH2 and SH3 domains of c-Src and activates c-Src. Moarefi et al. (42) have identified the Nef protein of HIV-1 as an Hck SH3-binder and activator of Hck. Thus, these specific SH2/SH3-binding partners have established the importance of protein-protein interaction in the regulation of SFKs. On the other hand, kinaseregulatory protein-protein interaction that takes place in the catalytic domain of SFKs has not been found until recently. In this study, we have shown that the activation of cSrc by Shc is mediated by a site-specific interaction between Shc and the catalytic domain of c-Src. Similar Src-activating interactions in the c-Src catalytic domain have been reported for trimeric G-proteins, Gsα and Giα (43) , and for an adaptor protein, β-arrestin 1 (44) . These studies, however, have not determined the interaction sites between the activator and c-Src. We have found that the activation segment of cSrc, which we originally called c-Src IDA (Inter-DFG-APE) region (27) , is responsible for the kinase-activating interaction of Shc. Surprisingly, the Shc-induced c-Src activation does not involve dephosphorylation of the carboxy-terminal pY527 ( Fig. 1D and 2B) . Then, how does the activation segment-mediated molecular interaction result in the c-Src activation? The c-Src activation segment, as found for other protein kinases, resides in the central part of the catalytic domain and is near the catalytic cleft of the enzyme.
Xu et al. (40) have demonstrated that the unphosphorylated activation segment adopts an α-helical structure that contributes to stabilize the closed conformation of c-Src. Theoretically, therefore, any effector interaction that disrupts this helical structure would bring about the relief of negative constraint and make the enzyme temporally active. Activation of the enzyme will then result in autophosphorylation of the activation segment that finally stabilizes the active conformation of the catalytic domain. As we have shown in Fig. 2D , the c-Src-Shc interaction was inhibited by the incubation with either unphosphorylated or phosphorylated IDA peptide.
The result suggests that Shc can bind to both phosphorylated and unphosphorylated activation segments. This is also evidenced by the fact that the Shc-activated c-Src, which should have undergone autophosphorylation, is still in complex with Shc (Fig. 1B) . Therefore, the molecular mechanism of c-Src activation by Shc seems to involve 1) Shc binding to the unphosphorylated activation segment, 2) structural alteration of the activation segment, 3) relief of the negative constraint of the catalytic domain, 4) autophosphorylation of the activation segment, and 5) stabilization of the active conformation of the catalytic domain. We have previously found a similar situation in which an antibody specific to the c-Src IDA peptide can stimulate c-Src activity in vitro (27) . As is the case with Shc-dependent activation (Fig. 2D) , the c-Src-activating antibody recognizes both phosphorylated and unphosphorylated IDA peptides and both forms of activation segment of c-Src. The antibody has no effect on the deregulated enzyme activity of vSrc, although it recognizes v-Src very well (27) . These results seem to provide a new insight of activation segment-mediated kinase regulation (see Table 1 ).
Towards a general scheme for protein kinase regulation-Every protein kinase has its own activation segment that can be identified by the conserved DFG and APE motifs in the catalytic domain (45) ( Table 1) . Thus, regulatory mechanism that involves protein-protein interaction at the activation segment will be of general importance for all protein kinases. Jeffrey et al. (46) have demonstrated that cyclin A and CDK2 constitute an active enzyme complex through the activation segment of CDK2. In the present study, we have identified Shc as a novel activation segment-binding partner of c-Src. Some other activation segment-interacting partners so far identified are inhibitors of the cognate kinases. For example, c-Cbl is a down-regulator for c-Src (47) and JAB/SOCS for Janus kinase 2 (48) . Recent studies also demonstrated that the activation segments of receptor/tyrosine kinases are specific binding sites for the Grb family of adaptor proteins that down-regulate the receptor/kinase activity (49, 50) . It is well known that phosphorylation of activation segment is indispensable for potentiation or up-regulation of many kinases. So, it seems very reasonable that the interaction of the above negative regulator proteins is dependent on the phosphorylation of the activation segment. Namely, only activated kinases are prone to down-regulation.
Our results, and those of others, indicate that identification of the activation segment-binding molecules will reveal the upstream activators, downstream substrates, and/or down-regulators of the kinase of interest. Thus, analyses of many unidentified partners are awaited. a PKA, human catalytic subunit α of protein kinase A (residues 185-209); PKC, rat protein kinase C α (residues 481-508); MAPK, human extracellular signal-regulated protein kinase 2/p42 mitogenactivated protein kinase (residues 165-195); CDK2, human cyclin-dependent protein kinase 2 (residues 145-172); c-Src, chicken c-Src (residues 404-432); EGFR, human epidermal growth factor receptor/kinase (residues 831-860); JAK2, mouse janus kinase 2 (residues 1001-1031); IGF1R, human insulin-like growth factor receptor-1 receptor/kinase (residues 1123-1152); TrkA, human TrkA/nerve growth factor receptor/kinase (residues 662-691). b Amino acid sequences of IDA regions are shown in one-letter code. c Phosphorylation sites are underlined. Surface plasmon resonance analysis using BIAcore 1000 (Pharmacia) was performed to determine the interaction between each of the GST-fusion Shc isoforms (0.5 µM) and immobilized GST-fusion Src IDA peptide. The extent of interaction, as revealed by resonance unit, was analyzed as a function of time. Association was monitored during the first 600 seconds, while dissociation was monitored in the next 300 seconds(B) . Significant association was observed with GST-P52 and GST-P66, but not with GST-P46 and GST alone. Schematic structures of GST-fusion constructs for full-length P52, fulllength P46, and various deletion mutants of P52. Results obtained with binding assay using BIAcore 1000 and kinase assays are presented. Dissociation constant (K D ) for each construct (means + standard deviations) was determined with more than three independent experiments. A minimal segment in P52, residues 29 to 39, was found to be capable of c-Src-binding, while an additional segment, residues 40 to 49, was required for the kinase-activating property of P52. Note that the c-Src-activating segment overlaps with one of the three α-helices (filled in black) in the PTB domain. (B)
Figure legends
Amino acid sequence of the c-Src-binding and kinase-activating segment in P52 Shc. Shaded box indicates the position of α1-helix (residues 40 to 47) that is absent from P46. An asterisk (methionine-46) indicates the position of the translation initiation for P46. An amino acid substitution was applied to this methionine residue (see Fig. 5A ). The lysates were also analy(H) zed for phosphorylation of Tyr-416 in anti-Src immunoprecipitates, for tyrosine phosphorylation of Stat1, 3, and 5b proteins, and for protein expression of p21/WAF1/Cip1, as in Figure 1D . Data shown are representative of three independent experiments.
